Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 17/20 | 0.65 |
| ▸ | ACVR1 | Q04771 | 17/20 | 0.65 |
| ▸ | BMPR1A | P36894 | 16/20 | 0.65 |
| ▸ | BMPR1B | O00238 | 15/20 | 0.65 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745958 | 0.83 | ACVRL1 (0.67) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL746915 | 0.81 | CYP11B1 (0.80) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL22655314 | 0.79 | BMPR1B (1.00) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL30404118 | 0.79 | BMPR1B (1.00) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL11529967 | 0.78 | BRD4 (0.55) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL769456 | 0.77 | ACVRL1 (0.53) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL769094 | 0.71 | ACVRL1 (0.66) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL22655321 | 0.71 | BMPR1B (1.00) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL399175 | 0.70 | BRD4 (0.56) | ACVRL1ACVR1BMPR1ABMPR1BTGFBR1 | |
| SCHEMBL1119388 | 0.70 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280954-B1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | UNIV SAARLAND (DE) | 2013-03-27 | — | — | EP | claimed |
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2280954-B1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | UNIV SAARLAND (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | HSD11B1, HSD11B2, CYP4A11 | ACVRL1 2633/4885ACVR1 1670/4885BMPR1A 2994/4885 |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | HSD11B1, HSD11B2, CYP11B1 | ACVRL1 3916/4885ACVR1 2946/4885BMPR1A 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.